论文部分内容阅读
目的探讨乳腺癌β3-微管蛋白表达与紫杉类药物化疗耐药发生的关系。方法对42例乳腺癌患者进行2~6个周期的含紫杉类药物方案化疗,并在化疗前及化疗的第2、4、6周期末检测β3-微管蛋白的表达,分析化疗疗效与β3-微管蛋白表达的相关关系以及化疗过程中β3-微管蛋白表达的改变。结果化疗前β3-微管蛋白的平均表达率为0.456±0.320,化疗总体有效率为57.1%,tubb3表达与紫杉类药物化疗有效率呈负相关。在化疗过程中,β3-微管蛋白表达呈上升趋势,并在第4疗程达到了统计学的差异。结论β3-微管蛋白是良好的紫杉类化疗敏感性预测因子,并且可能是紫杉类继发耐药的重要原因,在化疗前及化疗过程中检测其表达情况有助于化疗方案的选择。
Objective To investigate the relationship between the expression of β3-tubulin in breast cancer and the chemoresistance of taxanes. Methods Forty-two patients with breast cancer were treated with 2 ~ 6 cycles of chemotherapy with taxanes, and the expression of β3-tubulin was detected before chemotherapy and at the end of the 2nd, 4th and 6th cycles of chemotherapy. The effects of chemotherapy and β3-tubulin expression and the changes of β3-tubulin during chemotherapy. Results The average expression of β3-tubulin before chemotherapy was 0.456 ± 0.320, and the overall effective rate was 57.1%. The tubb3 expression was negatively correlated with the effective rate of chemotherapy with taxanes. During chemotherapy, β3-tubulin expression was on an upward trend and reached statistical significance at Week 4. Conclusion β3-tubulin is a good predictor of chemosensitivity to taxanes and may be an important cause of secondary drug resistance in taxanes. To detect the expression of β3-tubulin before chemotherapy and chemotherapy may be helpful for the selection of chemotherapy regimens .